NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Thursday that its first quarter revenues rose 226 percent year over year, driven by a 150 percent increase in the number of completed Cologuard colon cancer tests.

For the three months ended March 31, the diagnostics company reported revenues of $48.4 million, up from $14.8 million a year earlier, and blowing away the analyst estimate of $37.3 million.

Exact completed 100,000 Cologuard tests during the quarter, with an average recognized revenue per test of $485.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.